Fertomid 50 mg (Clomiphene)

Product Overview

Fertomid 50 mg is a prescription pharmaceutical product formulated by Cipla Limited that contains the active ingredient Clomiphene citrate. Each strip comprises ten tablets, each delivering a 50 mg dose of the selective estrogen receptor modulator. The medication is packaged in three available strengths: 30, 60, and 90 tablets per strip, allowing clinicians to select the most appropriate supply for their patients. It is specifically indicated for the treatment of female infertility associated with ovulatory dysfunction, including polycystic ovary syndrome (PCOS) and other conditions that result in irregular or absent ovulation. The drug’s oral administration route, established efficacy, and relatively low cost have contributed to its widespread use in reproductive endocrinology practices worldwide.

What is Fertomid 50 mg

Clomiphene citrate belongs to the class of non‑steridal selective estrogen receptor modulators (SERMs). Its mechanism of action involves binding to estrogen receptors in the hypothalamus, thereby reducing the negative feedback exerted by circulating estrogen on the hypothalamic‑pituitary axis. This inhibition leads to an increase in the secretion of gonadotropin‑releasing hormone (GnRH), which in turn stimulates the anterior pituitary to release higher amounts of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). The resulting rise in FSH promotes the recruitment and development of multiple ovarian follicles, while the LH surge triggers the final maturation and ovulation of the dominant follicle. The pharmacodynamic profile of Clomiphene has been extensively documented in peer‑reviewed literature, including reviews published by the National Institutes of Health and the U.S. Food and Drug Administration.

Uses and Benefits

Fertomid 50 mg is primarily employed to induce ovulation in women who experience oligo‑ or anovulation due to hormonal imbalances. In clinical practice, it is often the first‑line therapeutic option for patients with polycystic ovary syndrome, unexplained infertility, or hypothalamic amenorrhea. Studies have demonstrated that approximately 70 % of women with PCOS will ovulate in response to Clomiphene therapy, and about 30‑40 % of those will achieve clinical pregnancy within six treatment cycles. The medication offers several advantages: it is administered orally, does not require invasive procedures, and is associated with a well‑characterized safety profile when used under medical supervision. Additionally, the drug’s cost‑effectiveness makes it an accessible option in both high‑resource and low‑resource healthcare settings.

How It Works

The therapeutic effect of Clomiphene is rooted in its selective antagonism of estrogen receptors located in the hypothalamic region. By blocking estrogen’s inhibitory signal, the drug prompts the hypothalamus to release more GnRH, which stimulates the pituitary gland to secrete increased amounts of FSH and LH. Elevated FSH promotes the growth of multiple ovarian follicles, while the LH surge induces the final maturation and release of the dominant follicle, culminating in ovulation. This cascade of hormonal events is analogous to the natural physiologic process but is pharmacologically enhanced in women who have a defective feedback loop. The detailed mechanism is described in resources such as the NIH’s comprehensive drug information portal and the FDA’s drug labeling documents.

Dosage Guidelines

Standard therapeutic regimens for Fertomid 50 mg involve the oral administration of one tablet daily for five consecutive days, typically beginning on the third to fifth day of the menstrual cycle. This timing ensures that the drug’s stimulatory effect on the hypothalamic‑pituitary axis coincides with the early follicular phase, maximizing the chance of follicular recruitment. Subsequent cycles may be repeated after a minimum interval of 30 days, provided that the patient’s ovarian response is evaluated through ultrasound monitoring or serum estradiol measurements. Dosage adjustments are individualized; if multiple follicles develop or if the estradiol levels exceed a predefined threshold, the clinician may consider reducing the dose or extending the interval between cycles to mitigate the risk of ovarian hyperstimulation syndrome. It is essential that patients adhere strictly to the prescribed schedule and consult their healthcare provider before making any modifications.

Side Effects

Most adverse reactions to Clomiphene are mild and self‑limiting, typically resolving after the completion of the treatment cycle. Commonly reported side effects include hot flashes, abdominal discomfort, breast tenderness, nausea, and transient visual disturbances such as blurred vision or light sensitivity. Less frequently, patients may experience ovarian cysts, which are usually benign and resolve spontaneously, or mild weight gain due to fluid retention. In rare circumstances, more serious events such as ovarian hyperstimulation syndrome (OHSS), thromboembolic phenomena, or allergic reactions can occur. Patients should be instructed to seek immediate medical attention if they develop severe abdominal pain, rapid weight gain, shortness of breath, or visual changes that persist beyond the treatment period.

Warnings and Precautions

Clomiphene is contraindicated in individuals with a known hypersensitivity to the drug or any of its excipients, as well as in patients with active liver disease, ovarian cysts unrelated to polycystic ovary syndrome, or abnormal uterine bleeding of undetermined etiology. The medication should not be used during pregnancy or while breastfeeding, as its safety in these conditions has not been established. Prior to initiation, a thorough medical evaluation should assess for the presence of estrogen‑dependent tumors, thromboembolic disorders, or severe pelvic pathology that could be exacerbated by ovulation induction. Concomitant use of certain medications, including aromatase inhibitors, specific anti‑seizure agents, or other hormonal therapies, may alter the efficacy or safety profile of Clomiphene and should be reviewed by a qualified clinician. Ongoing monitoring through pelvic ultrasound and hormone assays is recommended to detect early signs of ovarian overstimulation.

Frequently Asked Questions

1. What is the typical success rate of Fertomid 50 mg? Clinical investigations indicate that ovulation occurs in roughly 70 % of treatment cycles, and approximately 30‑40 % of patients achieve pregnancy within six cycles of therapy, assuming regular intercourse or timed intercourse.
2. Can Fertomid be used for male infertility? Although Clomiphene has been explored off‑label for certain male fertility issues such as oligospermia, its primary indication remains female ovulation induction, and any use in men should be directed by a specialist after a comprehensive evaluation.
3. How should the tablets be stored? Store Fertomid 50 mg at room temperature, away from excessive moisture and direct sunlight. Keep the strip sealed until ready for use, and ensure that the medication is kept out of reach of children.
4. Is a prescription required to purchase Fertomid? Yes, Clomiphene is a prescription‑only medication in most jurisdictions. A thorough clinical assessment, including baseline hormonal testing and ultrasound evaluation, is required before a physician can prescribe the drug.
5. What should I do if I miss a dose during the treatment cycle? If a dose is inadvertently omitted, patients should not double up on the next dose. Instead, they should contact their prescribing physician for guidance; the missed tablet is typically not taken later in the same cycle.

For further scientific reference, consult the MedlinePlus entry on Clomiphene, the Drugs.com overview, the Wikipedia article, and the NIH drug information portal. Additional regulatory details are available on the U.S. Food and Drug Administration website.

Related Products

• Misoprost 600 mcg (Misoprostol)
• Misoprost (Misoprostol)
• Misoprost 200 mcg (Misoprostol)
• Misoprostol 600 mcg (Generic)
• Misoprostol 200 mcg (Generic)
• Pantosec D SR (Pantoprazole/Domperidone)
• Pantosec D 50 Mg (Pantoprazole/Domperidone)
• Rabicip 10 mg (Rabeprazole)
• Rabicip (Rabeprazole)
• Pantosec 40 mg (Pantoprazole)
• Rabicip 20 mg (Rabeprazole)
• Rabeprazole 20 mg (Generic)